Scarica l'app Stockscreener
73.31
0.83%
-0.61
Pre-mercato:
73.61
0.30
+0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$73.92
Aprire:
$73.19
Volume 24 ore:
219.70K
Relative Volume:
0.50
Capitalizzazione di mercato:
$1.64B
Reddito:
$883.37M
Utile/perdita netta:
$71.37M
Rapporto P/E:
21.87
EPS:
3.3516
Flusso di cassa netto:
$150.90M
1 W Prestazione:
-1.31%
1M Prestazione:
-4.42%
6M Prestazione:
-22.82%
1 anno Prestazione:
+11.11%
Intervallo 1D:
$72.82
$74.43
Intervallo di 1 settimana:
$72.20
$76.00
Portata 52W:
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Nome
Ani Pharmaceuticals Inc
Settore
Telefono
(218) 634-3500
Indirizzo
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
73.31 | 1.64B | 883.37M | 71.37M | 150.90M | 3.3516 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-14 | Iniziato | Jefferies | Buy |
| 2025-03-12 | Iniziato | JP Morgan | Overweight |
| 2024-12-11 | Iniziato | Leerink Partners | Outperform |
| 2024-10-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-15 | Iniziato | CapitalOne | Overweight |
| 2023-08-22 | Reiterato | H.C. Wainwright | Buy |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2022-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-02 | Iniziato | Truist | Buy |
| 2020-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-05-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Reiterato | Canaccord Genuity | Buy |
| 2017-07-31 | Iniziato | Canaccord Genuity | Buy |
| 2017-02-22 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Iniziato | Raymond James | Strong Buy |
| 2016-05-24 | Downgrade | Standpoint Research | Buy → Hold |
| 2015-11-13 | Iniziato | Standpoint Research | Buy |
| 2015-09-28 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Reiterato | Oppenheimer | Outperform |
| 2015-08-04 | Reiterato | ROTH Capital | Neutral |
| 2015-07-31 | Reiterato | Oppenheimer | Outperform |
| 2015-07-15 | Reiterato | ROTH Capital | Neutral |
| 2015-06-23 | Reiterato | Oppenheimer | Outperform |
| 2015-05-18 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Reiterato | Oppenheimer | Outperform |
| 2015-04-10 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Reiterato | ROTH Capital | Buy |
| 2015-02-18 | Reiterato | Oppenheimer | Outperform |
Mostra tutto
Ani Pharmaceuticals Inc Borsa (ANIP) Ultime notizie
Risk Analysis: Will ANI Pharmaceuticals Inc announce a stock splitTrade Performance Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
Oliver Luxxe Assets LLC Invests $1.82 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Completion of Merger - Yahoo
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals Expands Ophthalmology Reach As Valuation Signals Upside Potential - Yahoo Finance
Assessing ANI Pharmaceuticals (ANIP) Valuation After Rare Disease Momentum And Alimera Acquisition - Sahm
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - TradingView
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Guggenheim Remains a Buy on ANI Pharmaceuticals (ANIP) - The Globe and Mail
ANIP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story - simplywall.st
EPS Watch: Can ANI Pharmaceuticals Inc lead its sector in growthQuarterly Earnings Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - TradingView
ANIP PE Ratio & Valuation, Is ANIP Overvalued - Intellectia AI
IBRX Stock Jumps on Progress in NK Cell Therapy Production - TradingView
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia - Bitget
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - The Globe and Mail
ANI Pharmaceuticals Insiders Unload $584K in Shares Amid 18-Month Selling Streak - AlphaStreet
234,219 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Divisadero Street Capital Management LP - MarketBeat
Apis Capital Advisors LLC Purchases 36,000 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Form 4 ANI Pharmaceuticals Inc For: 13 March By Investing.com - Investing.com Australia
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
Ani Pharmaceuticals SVP Cook sells $36k in stock - Investing.com
Ani Pharmaceuticals SVP Cook sells $36k in stock By Investing.com - Investing.com South Africa
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Insider Sells 3,162 Shares of Stock - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 4,772 Shares - MarketBeat
Ani pharmaceuticals SVP Rowland sells $357k in stock By Investing.com - Investing.com South Africa
Ani pharmaceuticals SVP Rowland sells $357k in stock - Investing.com
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ANI Pharmaceuticals (ANIP) legal chief sells 500 shares under 10b5-1 plan - Stock Titan
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView
ANI Pharmaceuticals, Inc. $ANIP Stock Position Reduced by Kennedy Capital Management LLC - MarketBeat
Sizing Up ANI Pharmaceuticals (ANIP) After Recent Share Price Pullback - Yahoo Finance
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
How ANI’s Reaffirmed 2026 Guidance and Rare Disease Push Will Impact ANI Pharmaceuticals (ANIP) Investors - simplywall.st
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
ANIP SEC FilingsAni Pharmaceutic 10-K, 10-Q, 8-K Forms - Stock Titan
ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B - MarketBeat
ANI Pharmaceuticals at Barclays Conference: Rare Disease Focus Drives Growth - Investing.com Canada
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - TradingView
ANI Pharmaceuticals Targets $1.1B 2026 Revenue as Cortrophin Sales Surge, Gout Launch Set for Midyear - MarketBeat
Insider Sell: Krista Davis Sells Shares of ANI Pharmaceuticals I - GuruFocus
ANI Pharmaceuticals (NASDAQ: ANIP) executive sells shares, withholds stock for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) CEO stock withheld to cover taxes - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief sells 6,572 shares under 10b5-1 plan - Stock Titan
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
ANIP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ani pharmaceuticals head of rare disease sells $30k in stock - Investing.com Nigeria
Ani Pharmaceuticals Inc Azioni (ANIP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):